Apellis Pharmaceuticals (Apellis Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-05-01), Apellis Pharmaceuticals's share price is $46.03. Apellis Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.03. Hence, Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

APLS's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Apellis Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.81. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.03.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -32.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -18.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -33.10% per year.

During the past 11 years, Apellis Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 14.00% per year. The lowest was -96.30% per year. And the median was -33.05% per year.

Apellis Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Apellis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Apellis Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	46.03	/	-5.031
	=

Apellis Pharmaceuticals's Share Price of today is $46.03.
Apellis Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.03.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Apellis Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (Apellis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Executives

Karen Lewis	officer: Chief People Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Mark Jeffrey Delong	officer: Senior Vice President	100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
James George Chopas	officer: See Remarks	950 WINTER STREET, WALTHAM MA 02451
Adam J. Townsend	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson	officer: General Counsel	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets	officer: Chief Operating Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Jeffrey Eisele	officer: See Remarks	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson	officer: Chief Technical Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan	officer: Chief Financial Officer	800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois	director, 10 percent owner, officer: Chief Executive Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Caroline Baumal	officer: Chief Medical Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop	director	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels	director	505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014